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Parvovirus B19 (B19) infection can occur during
acute lymphoblastic leukemia and persistent
viral infection can occur despite intravenous
immunoglobulin administration. Here, evidence
is presented that resolution of persistent B19
infection in an acute lymphoblastic leukemia
patient may be associated with the simultaneous
strengthening of antigen-specific B cell memory
against the B19 capsid protein VP2 and diminu-
tion in the memory response against the B19
non-structural protein 1 (NS1). Determination
of antigen-specific B cell memory status may
enhance the serological and molecular analyses
of persistent B19 infection. J. Med. Virol. 78:
125–128, 2006.  2005 Wiley-Liss, Inc.
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INTRODUCTION
Parvovirus B19 (B19) is the causative agent of disease
in both immunocompetent and immunocompromised
individuals [Broliden, 2001; Corcoran and Doyle, 2004].
Specifically with respect to the immunocompromised
status, there have been a number of recent reports of
B19-associated disease in acute lymphoblastic leukemia
of children [Heegaard and Schmiegelow, 2002; Savasan
and Ozdeir, 2003; Kerr et al., 2003a; Fattet et al., 2004].
Although it has been suggested that childhood acute
lymphoblastic leukemia may be associated with prior
B19 exposure [Savasan and Ozdeir, 2003], this causal
link remains unproven. In fact, recent work by Isa et al.
[2004]has shown thatB19 exposure, inutero, is unlikely
to be associated with the subsequent onset of acute
lymphoblastic leukemia, as judged by the absence of
detectable B19 DNA from Guthrie cards of children
(n¼54) who subsequently went on to develop acute
lymphoblastic leukemia.
Administration of intravenous immunoglobulin is the
main treatment for the symptoms associated with per-
sistent B19 infection, such as pancytopenia and chronic
anemia, in immunocompromised patients [Broliden,
2001] although the benefit of intravenous immunoglo-
bulin administration in acute lymphoblastic leukemia
patients has recently been questioned [Fattet et al.,
2004]. Conceivably, the current lack of standardization
of B19 IgG levels present in intravenous immunoglobu-
lin may be responsible for this uncertainty with respect
to efficacy. To date, most studies on the pattern of B19
serology and viraemia during acute lymphoblastic
leukemia have focused solely on the detection of B19
IgG and IgM and viral DNA [Heegaard and Schmiege-
low, 2002; El-Mahallawy et al., 2004; Fattet et al., 2004].
Two recent reports [Kerr et al., 2003a;Fattet et al., 2004]
have alluded to importance the overall individual
patient response, and by implication the cellular
immune response, in successful eradication of B19
infection. Evidence is presented in this report that the
establishment of B cell memory is coincident with the
clearance of circulating B19 and resolution of B19-
associated symptoms.
METHODS
A previously well 5-year-old girl presented with
pyrexia, cough, bruising, and a purpuric rash. Bone
marrow examination confirmed the diagnosis of CD10þ
Grant sponsor: Commission of the European Communities;
Grant number: QLK2-CT-2001-00877.
A. Corcoran’s present address is Biotrin, 93, The Rise, Mount
Merrion, Co. Dublin, Ireland.
*Correspondence to: Dr. S. Doyle, Department of Biology and
National Institute for Cellular Biotechnology, National Univer-
sity of Ireland, Maynooth, Co. Kildare, Ireland.
E-mail: sean.doyle@nuim.ie
Accepted 30 September 2005
DOI 10.1002/jmv.20513
Published online in Wiley InterScience
(www.interscience.wiley.com)
 2005 WILEY-LISS, INC.
acute lymphoblastic leukemia and she commenced on
induction chemotherapy with the MRC ALL 97 (v99)
protocol (regimen B). After induction therapy she
started consolidation chemotherapy. She responded
well, but in week 17 she was anemic and a bone marrow
aspirate showed erythroid hypoplasia. Over the follow-
ing 4 weeks she became transfusion-dependent, requir-
ing nine packed red cell transfusions. Subsequent bone
marrow aspirates confirmed erythroid hypoplasia with
no relapse of acute lymphoblastic leukemia.Chemother-
apy was commenced on T¼3months (relative to T¼0
for initial B19 serological and nucleic acid testing) and
also administered at months 3, 16, and 19. Parental
permission was obtained for specimen collection.
Total B19-specific IgG for capsid VP2 (VP2-N) was
determined by commercial EIA (Biotrin International,
Dublin, Ireland). B19 IgM was assessed according to
Brown et al. [1989]. B19 IgG reactivity against linear-
ized VP1 (VP1-D), VP2 (VP2-D), and NS1 was deter-
mined using immunoassay formats as described
previously [Corcoran et al., 2000]. B19 DNA levels were
assessed as described previously [Hicks et al., 1995;
Braham et al., 2004] and were quantified using a B19
DNA International Standard preparation [Saldanha
et al., 2002]. In addition, cell proliferation studies and
cytokine quantitation were carried out as described
elsewhere [Corcoran et al., 2000]. B cell memory was
analyzed using a B19-specific B cell ELISpot assay as
described by Corcoran et al. [2004]. Briefly, nitrocellu-
lose-lined plates (96 well) (Millipore, Bedford, MA) were
coated with either capsid VP2 (VP2-N; 10 mg/ml),
denatured VP2 (VP2-D; 10 mg/ml), denatured VP1
(VP1-D; 10 mg/ml), NS1 (10 mg/ml), or rabbit anti-human
IgG (DakoA/S, Glostrup, Denmark) (10 mg/ml) in 50mM
sodiumcarbonate buffer pH9.6, overnight at 48C (rabbit
anti-human IgG facilitates detection of total IgG-
secretingB cells to insure thatmemoryB cell activation,
viaStaphylococcusaureusCowanstrain1 cells and IL-2,
had occurred). Plates were washed with phosphate-
buffered saline (PBS) and blocked (20%(v/v) FCS in
RPMI medium). Cells (post-activation), at 1 107,
1 106, 1105, and 1 104 cells/well were added to
the plates and secreted IgG was detected using biotiny-
lated rabbit anti-human IgG/streptavidin-conjugated
alkaline phosphatase (Sigma-Aldrich, Dorset, UK1) and
BCIP/NBT precipitating substrate (Sigma-Aldrich).
Spots were averaged from triplicate wells and resultant
data reported as the mean number of spot forming cells
(SFC)/million starting cells.
RESULTS
Initial serological testing (T¼0), using a B19 VP2
capsid-based immunoassay, for B19 IgG/M proved
negative, however B19 DNA positivity was confirmed
by both real-time PCR and by dot blot hybridization
[Hicks et al., 1995; Braham et al., 2004] (Fig. 1).
Treatment with intravenous immunoglobulin was com-
menced, and although logarithmic reductions in B19
viral loadwere observed post-treatment, viral clearance
was not achieved, as judged by a continual elevation
in plasma B19 DNA levels, until month 31 (Fig. 1).
Serological analysis of a specimen obtained from the
individual at T¼ 1 (Fig. 1) demonstrated the presence of
high levels of intravenous immunoglobulin-derived B19
VP2 IgG (index value 5.76; reactivity> or¼1.1), in
addition todetecting thepresence ofB19NS1 IgG (Index
value 3.22). No IgG was detected which was reactive
against linear epitopes of either VP1 or VP2 proteins
(VP1-D and VP2-D; data not shown). At T¼2, the B19
VP2 IgG index value was 2.31, while that for B19 NS1
had decreased to 0.77 (seronegative status).
Freshly isolated peripheral blood mononuclear cells
(PBMCs), from the T1 specimen, were stimulated
ex vivo, with both B19 VP1 and VP2 proteins. Although
phytohaemagglutinin (PHA) stimulation resulted in
significant stimulation index (SI (mean standard
deviation): 1062.92508.81, n¼ 3), no detectable T cell
stimulationwas evident following exposure of PBMCs to
either VP1 (SI: 0.30.2) or VP2 (SI: 1.7 0.7). Cytokine
analysis of culture supernatants likewise indicated a
deficit in the presence of cytokines associated with
either a Th1 (interferon-g) or Th2 (IL-4 and IL-5)
immune response following B19 antigen stimulation
(data not shown). Interferon-gwas detectable in culture
supernatants following PBMC stimulation with PHA
(data not shown). Subsequent analysis of a second
specimen (T2) obtained 5 months after the initial
sample, demonstrated the continued absence of a
detectable cellular immune response against both B19
VP1 and VP2 proteins. Interestingly, significant PBMC
proliferation was evident following stimulation with
B19 NS1 protein (SI: 8.71.7) (Fig. 2A). Again,
however, there was no evidence of B19-specific cytokine
production (IL-2, interferon-g, IL-4, and IL-5) against
B19 VP1, VP2, or NS1 proteins.
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Fig. 1. Effect of multiple intravenous immunoglobulin administra-
tion on serum parvovirus B19 levels (B19 DNA (IU/ml)). Initial
serological and virological analyses were performed at T¼ 0. Speci-
mens for analysis of T cell immunity and B cell ELISpot were obtained
at T¼ 1 (22 months) and 2 (27 months), respectively. Chemotherapy
was commenced on T¼3 months (relative to T¼ 0 for initial B19
serological and nucleic acid testing), chemotherapy was also adminis-
tered at months 3, 16, and 19. IVIG: Intravenous immunoglobulin.
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It can be seen fromFigure 2B that no B cell memory is
evident against either linear epitopes of B19VP1 orVP2
proteins, however significant B cell memory is detect-
able against the B19 NS1 protein (123.3 20.2 SFC/106
cells; meanSD) in specimen T1. In addition, a small
though detectable level of B cell memory was detectable
against B19 VP2 capsid protein (5.35.7 SFC/106 cells;
meanSD). Interestingly, upon analysis of specimen
T2, it was observed that the memory B cell level against
the NS1 protein had diminished (tenfold). However, the
level of detectable memory against capsid VP2, and to a
lesser extent the VP1 unique region, had increased with
respect to the initial analysis, (VP2-N: 13 2, VP1-D:
3 2, VP2-D: 1.7 0.6, NS1-D: 93.6 SFC/106 cells).
This apparentdevelopment of a functionalhost response
against parvovirus B19 capsid protein VP2 was accom-
panied by a resolution of viral disease symptoms and
diminution of plasmaB19DNA levels to less than 102 IU
B19 DNA/ml.
DISCUSSION
Persistent infection with parvovirus B19 (B19) is
described in an acute lymphoblastic leukemia patient
despite the administration of intravenous immunoglo-
bulin therapy. The persistent B19 infection was asso-
ciated with the detection of NS1 IgG reactivity, in
addition to evidence of T cell immunity and B cell
memory directed against B19 NS1. Furthermore,
evidence is presented that the establishment and
enhancement of B cell memory, directed against the
capsid proteins of B19, was associated with diminution
of B19 viremia and resolution of related disease
symptoms in the acute lymphoblastic leukemia patient.
It is evident that multiple administration of intrave-
nous immunoglobulin throughout the treatment period
was insufficient to eliminate B19 viraemia, indeed the
viral load remained between 103 and 1010 IU B19 DNA/
ml until the final intravenous immunoglobulin treat-
ment at month 23. The precise origin (i.e., patient- or
intravenous immunoglobulin-derived) of B19 VP2 IgG
detectable in specimen T1 is unclear, although the
presence of B19 NS1 IgG does indicate that patient
antibody production capability was intact. Nonetheless,
the use of intravenous immunoglobulin therapy for the
elimination B19 viraemia remains unproven, indeed
a recent study [Fattet et al., 2004], which reported
variable success with intravenous immunoglobulin
treatment in acute lymphoblastic leukemia, recom-
mended the treatment only in cases of persistent
pancytopenia or clinicalmanifestations ofB19 infection.
However, intravenous immunoglobulin therapy has
been shown to be successful for the treatment of B19-
associated chronic fatigue syndrome [Kerr et al., 2003b].
Ultimately, the efficacy of intravenous immunoglobulin
therapy for the elimination of B19 viremia will only
become apparent when the level of B19 IgG present in
intravenous immunoglobulin preparations is reported
in terms of B19 IgG IU/ml as previous studies have
indicated variable B19 IgG levels (64.7 17.5 IU/ml;
(n¼ 30)) in pooled solvent-detergent treated plasma
[Daly et al., 2002].
Although initially thought to beamarker of persistent
infection only [von Poblotzki et al., 1995], the detection
of NS1 IgG has also been shown to be present during
acute B19 infection in 61%–69% of individuals
[Hemauer et al., 2000; Ennis et al., 2001]. Moreover,
significant T cell responses to NS1 have also been
reported in recently infected individuals and patients
who developed chronic arthropathy following B19
infection [Mitchell et al., 2001]. It is clear from the
present study, however, that immunity to NS1 does
not appear to be consistent with clearance of B19
infection, at least in this individual suffering from acute
J. Med. Virol. DOI 10.1002/jmv
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Fig. 2. Evaluation of PBMC proliferative response and antigen-
specific B cell memory in acute lymphoblastic leukemia. A: Specific
proliferative response to human parvovirus B19 proteins VP1 (VP1-D),
VP2 (VP2-N), and NS1 in addition to the positive control mitogen,
phytohaemaggultinin (PHA), at T¼2. Results are expressed as
stimulatory indices (SI) and are the meanSD of triplicate wells.
B: Parvovirus B19-antigen-specific B cell memory at T¼1 and 2.
Results of B cell memory are expressed as B19-specific spot-forming
cells (SFCs)/number of starting cells and are the meanSD of
triplicate wells. Individual ELISpot microplates were coated with the
following B19 proteins: native (capsid) VP2 (VP2-N), denatured VP2
(VP2-D), denatured VP1 (VP1-D), and NS1. Human IgG detection
using rabbit anti-human IgG was used to confirm that total B cell
activation had occurred (data not shown). Note: B19 NS1 protein
response¼ 123.320.2 SFC/106 cells in specimen T1.
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lymphoblastic leukemia. In addition, the presence of
high titer B19 VP2 IgG, in the absence of detectable
cellular immunity, also appears to be insufficient to
completely ameliorate B19 viraemia.
However, the establishment of B cell memory against
capsidVP2, and to a lesser extentVP1,mayplay a role in
the clearance of B19 viremia. We have previously
reported evidence of B cell memory against B19 capsid
proteins in immunocompetent individuals [Corcoran
et al., 2004], and the data presented above represent the
first determination of a similar pattern of B cell memory
in acute lymphoblastic leukemia, coincident with the
resolution of B19 viraemia and symptoms. Assessment
of antigen-specific B cell memory also facilitates dis-
crimination between intravenous immunoglobulin- and
individual-derived B19 IgG, respectively, which is
significant in determining the seroconversion status
of the individual. Interestingly, no evidence of B cell
memory was evident against B19 NS1 in five immuno-
competent individuals [Corcoran et al., 2004] thereby
suggesting that the presence of B cell memory against
this protein may be indicative of memory dysfunction
in acute lymphoblastic leukemia. Resolution of B19
viraemia to less than 102 IU/ml B19 DNA in the patient
was coincident with a threefold increase in detectable B
cellmemory against capsid VP2 (and a tenfold reduction
with respect to NS1).
In conclusion, we suggest that determination of
antigen-specific B cell memory should accompany the
serological and molecular investigation of persistent
B19 viraemia, and associated diseasemanifestations, in
immunocompromised individuals.
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